Item 7.01. Regulation FD Disclosure.
On July 25, 2022, Strata Skin Sciences (the “Company”) announced the U.S.
commercial launch of TheraClear®X, a non-invasive, in-office acne treatment
targeting the root causes of mild to moderate acne, including comedonal,
pustular and inflammatory acne vulgaris.
The information set forth under this Item 7.01, including Exhibit 99.1, is being
furnished and shall not be deemed “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of such section, nor shall such information be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits: 99.1 Press release, dated July 25, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses
postbrexitcompliance.com 